Last mentioned: Mar 22, 2026
Litigation Filed
Pomerantz LLP announces the filing of a class action lawsuit against Nektar.
DCAT Week 2026
LOTTE Biologics engages in high-level partnership talks in New York City.
FY 2025 Earnings
Official reporting of full-year financial results and 2026 clinical guidance.
Cibotercept Data
Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients.
ADC Expansion
Completion of specialized ADC manufacturing lines at the Syracuse facility.
KER-050 Expansion
Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
Capital Infusion
Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
Songdo Groundbreaking
Construction begins on the first Mega Plant in Songdo, South Korea.
Syracuse Acquisition
LOTTE Biologics completes the acquisition of the Syracuse, NY plant from Bristol Myers Squibb.
Partnership Termination
BMS and Nektar officially end their global clinical development collaboration.
Phase 3 Failure
Lead melanoma trial fails to meet primary endpoints, causing stock to plummet.
BMS Partnership
Nektar signs a $3.6B deal with Bristol Myers Squibb for bempegaldesleukin.
Pomerantz LLP has initiated class action litigation against Nektar Therapeutics, alleging the company made false or misleading statements regarding its clinical programs and business prospects. The lawsuit seeks to recover damages for investors following significant stock volatility linked to the company's oncology pipeline performance.
Medical technology firm Nyxoah and immunology specialist Alumis both reported quarterly earnings that fell short of analyst expectations by $0.04 per share. The misses reflect the high capital intensity of late-stage clinical development and the commercial infrastructure build-out required for upcoming product launches.
Both Nyxoah and Alumis reported quarterly earnings that missed analyst expectations by $0.04 per share, reflecting the high operational costs of late-stage clinical trials and pre-commercialization activities. Despite the financial shortfall, both companies remain on track with pivotal regulatory and clinical milestones in the sleep apnea and immunology sectors.
Recent clinical findings indicate that patients with Mild Cognitive Impairment (MCI) and dementia face a significantly higher risk of developing new cardiovascular indications requiring anticoagulation therapy. This discovery underscores the critical link between cognitive decline and systemic vascular health in the aging population.
New research indicates that patients with Mild Cognitive Impairment (MCI) and dementia are at a significantly higher risk for developing cardiovascular conditions requiring anticoagulants. This finding underscores the clinical challenge of managing stroke prevention in cognitively impaired populations with high fall risks.
LOTTE Biologics is set to engage with global pharmaceutical leaders at DCAT Week 2026 in New York, aiming to secure strategic partnerships and showcase its expanding CDMO capabilities. The move underscores the company's aggressive push to become a top-tier global contract manufacturer by leveraging its Syracuse and Songdo facilities.
LOTTE Biologics is attending DCAT Week 2026 in New York to secure high-value global partnerships and solidify its position in the CDMO market. This move underscores the company's aggressive strategy to leverage its U.S. manufacturing footprint and upcoming South Korean capacity.
Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
Halozyme Therapeutics reported robust Q4 2025 results, driven by record royalty revenue from its ENHANZE drug-delivery platform and key partnerships with Roche and Argenx. The company is positioning 2026 as a transformative year, centered on the high-stakes commercial launch of subcutaneous Opdivo in collaboration with Bristol Myers Squibb.
Halozyme Therapeutics reported a strong revenue beat of $451 million for the fourth quarter, driven by its ENHANZE platform royalties, yet surprised investors with a significant non-GAAP EPS miss of $2.44. The discrepancy suggests substantial one-time charges or strategic shifts that contrast with the company's robust top-line growth.